ReviewPharmaceuticals (Basel, Switzerland)2026
From DNA-Encoded Chemistry to Tumor-Targeted Small Molecule Therapeutics.
Review in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unlike conventional screening methods, which are limited by library size, DNA-encoded chemical library (DEL) technology enables the simultaneous interrogation of billions of compounds, each uniquely barcoded with DNA tags. These libraries can be screened through affinity-based capture and decoded using high-throughput sequencing. DEL-derived ligands can be conjugated to cytotoxic agents or radioactive isotopes, facilitating the creation of highly selective therapeutics that target diseased cells while minimizing off-target effects. This article explores the use of DELs for identifying high-affinity small organic ligands for the development of small molecule-radio conjugates (SMRCs) and small molecule-drug conjugates (SMDCs).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.